{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:19:45Z","timestamp":1755796785227},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.beha.2011.09.007","type":"journal-article","created":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T20:34:39Z","timestamp":1320438879000},"page":"515-522","source":"Crossref","is-referenced-by-count":2,"title":["What is the optimal induction strategy for older patients?"],"prefix":"10.1016","volume":"24","author":[{"given":"Elihu","family":"Estey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2011.09.007_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.09.007_bib2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3324\/haematol.13309","article-title":"Acute Leukemia French Association (ALFA). Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia","volume":"93","author":"Malfuson","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2011.09.007_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"United Kingdom National cancer Research Institute Haematological Oncology clinical Studies group and acute myeloid leukaemia Subgroup. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"Wheatley","year":"2009","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.beha.2011.09.007_bib4","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2011.09.007_bib5","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"issue":"9757","key":"10.1016\/j.beha.2011.09.007_bib6","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","volume":"376","author":"Krug","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.beha.2011.09.007_bib7","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2010-02-270330","article-title":"Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience","volume":"116","author":"Medeiros","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2011.09.007_bib8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.beha.2011.09.007_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2011.09.007_bib10","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2011.09.007_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood.V95.1.72","article-title":"Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB","volume":"95","author":"Estey","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2011.09.007_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3324\/haematol.12366","article-title":"Relapse and death during first remission in acute myeloid leukemia","volume":"93","author":"Yanada","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2011.09.007_bib13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.09.007_bib14","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study","volume":"28","author":"Walter","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.09.007_bib15","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/blood.V90.12.4719","article-title":"Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work","volume":"90","author":"de Lima","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2011.09.007_bib16","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2010-07-297143","article-title":"A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia","volume":"117","author":"Fehniger","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2011.09.007_bib17","first-page":"150","article-title":"A phase II study of lenalidomide for previously untreated deletion (del) 5q acute myeloid leukemia (AML) patients age 60 or older who are not candidates for remission induction chemotherapy (Southwest Oncology Group Study S0605)","volume":"116","author":"Sekeres","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"10.1016\/j.beha.2011.09.007_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2011.09.007_bib19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2011.09.007_bib20","first-page":"1644","article-title":"Prior therapy with DNA methyltransferase inhibitors (DNMTI) predicts for lower remission rates and worse survival in secondary acute myeloid leukemia patients (sAML) receiving remission induction therapy","volume":"116","author":"Mohan","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"10.1016\/j.beha.2011.09.007_bib21","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/cncr.25598","article-title":"Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome","volume":"117","author":"Bello","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2011.09.007_bib22","series-title":"Handbook of statistics in clinical oncology","first-page":"411","article-title":"Graphical methods for evaluating covariate effects in the Cox model","author":"Thall","year":"2001"},{"issue":"21","key":"10.1016\/j.beha.2011.09.007_bib23","first-page":"904","article-title":"Quantitative effect of age in predicting empirically-defined treatement-related mortality and resistance in newly diagnosed A: case against age alone as primary determinant of treatment assignment","volume":"116","author":"Walter","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T03:21:39Z","timestamp":1593228099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1521692611000879"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.09.007","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}